Acutaas Chemicals Ltd

- The company has not explicitly mentioned any new fundraising plans through debt or equity in the provided transcript. - Current capex and investments, such as INR220 crores for capex and around INR130-150 crores invested in the Indichem joint venture, are being funded through existing cash on hand and strong cash flow generation. - There is no mention of any plans for raising additional funds via debt or equity in the near future. - The company appears confident in its financial position to fund ongoing and planned projects without external fundraising at present.

- Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex. - Indichem joint venture (South Korea) investment: INR 130 crores invested so far out of total INR 200 crores announced; capex progressing as per plan; additional investment possible this quarter. - Battery chemicals segment: No specific capacity announced for two new products; second phase capex part of the INR 220 crore plan. - Ankleshwar plant utilization currently at 40%; growth till FY '28 expected with possible incremental pharma intermediate capex after 1.5 years based on market conditions. - Indichem JV capex started 4 months ago, expected completion by calendar end. - The company has sufficient cash and strong cash flows to fund these investments.

- Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). - CDMO business is projected to cross INR 1,000 crores revenue by FY 2028, driven by multiple validated products and new contracts (Page 12, 17). - Battery chemical segment, especially products like vinyl carbonate (VC) and fluoroethylene carbonate (FEC), is in early stages with capacity and contracts in place; further products are planned for commercialization in mid-FY 2027 onwards (Page 8, 16). - Semiconductor chemical verticals (including Baba Fine Chem and Indichem JV) are expected to contribute meaningfully by 2028 with high EBITDA margins (Page 13, 16). - Quality growth focus in pharma intermediates, with exiting low-margin products, contributing to steady high single-digit growth (Page 12). - Overall, strong visibility on contracts and pipeline products support aggressive scaling up of all business verticals through FY 2027 and beyond (Page 17).

- Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years. - EBITDA margin guidance for FY '26 has been upgraded to 30%-35% from an earlier 28%. - The company targets INR 1,000 crores in CDMO business revenue by FY '28, comprising multiple segments, not just anticancer. - Profit margins are expected to improve due to better product mix, operational efficiencies, and scale-up in new segments like semiconductor chemicals and battery electrolyte additives. - Long-term supply contracts with pricing linked to raw materials and currency fluctuations provide stable margins, especially in additives business. - Expansion in R&D and continued process optimization will support margin enhancement and profitability. - Overall, PAT has shown strong growth with 133.7% increase in the quarter and more than doubled in 9 months FY '26, reflecting robust earnings momentum.

- The company has good visibility of contracts for FY '27 and beyond, expecting fast scaling of its business. - For the additives business, there are fixed pricing contracts in place with variability linked to raw materials and currency. - The anticancer CDMO segment has long-term supply contracts, with projections extending through FY '28. - Four new CDMO products validated in the current financial year are expected to start contributing from FY '27. - Sampling and validation for additional CDMO products are underway, reinforcing a strong pipeline. - Battery chemical orders for VC and FEC products are already in hand with good revenue visibility for FY '27. - Two additional battery chemical products are expected to contribute to revenues starting mid-FY '27. - Indichem joint venture's plant capex is to be completed by calendar year 2026, with revenue expected from next year. - Overall, the company aims to achieve INR 1,000 crores from CDMO business by FY '28, encompassing multiple projects.